1. Tailoring Antiplatelet Therapy in PCI

2. Program Goals

3. Antiplatelet Options for PCI

4. Pre-Cath Antiplatelet Treatment 2014 AHA/ACC NSTE-ACS Recommendations

5. Clopidogrel Pretreatment

6. ACCOAST Major Efficacy and Bleeding Endpoints

7. Goal of Pretreatment

8. CURE

9. 2014 ACC/AHA Guideline Recommendations Early Invasive and Ischemia-Guided Strategies

10. Not All Platelet Inhibition Is the Same

11. Case

12. PLATO Efficacy and Bleeding Endpoints

13. Case (cont)

14. 2014 ACC/AHA Guideline Recommendations

15. Case 2

16. Case 2 (cont)

17. Case 2 (cont) Angiogram Findings

18. Cangrelor The CHAMPION PHOENIX Trial

19. Crushed Ticagrelor vs Cangrelor

20. Mechanism of Action: P2Y12 Agents

21. Decisions Guiding Long-Term Continuation of DAPT

22. Predicting Benefit and Harm of DAPT Beyond 1 Year After PCI

23. Platelet Function Testing, Genetic Testing, and Switching of P2Y12 Inhibitors

24. Platelet Function Testing Potential Uses

25. Abbreviations

26. Abbreviations (cont)